Posted by Michael Wonder on 03 Dec 2019
Psoriasis sufferers, asthmatics, UCD patients to save thousands as key medicines are added, expanded on the PBS
1 December 2019 - Australians living with psoriasis, severe asthma and urea cycle disorder are set to experience significant financial relief, with breakthrough medicines to be added and expanded on the Pharmaceutical Benefits Scheme, on December 1.
Patients with moderate to severe plaque psoriasis will have access to the new psoriasis drug Skyrizi (risankizumab).
More patients with severe eosinophilic asthma will have access to the currently listed asthma medicines Fasenra (benralizumab) and Nucala (mepolizumab), after the access criteria was expanded.
